During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...
Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...
Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback